LCAR-B4822M CAR-T Cell Immunotherapy
LCAR-B4822M
Phase 1 small_molecule active
Quick answer
LCAR-B4822M CAR-T Cell Immunotherapy for Refractory or Relapsed Multiple Myeloma is a Phase 1 program (small_molecule) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Legend Biotech Corp
- Indication
- Refractory or Relapsed Multiple Myeloma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active